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Abstract
For decades, the mineralocorticoid receptor (MR) antagonists have been used for the 
management of cardiovascular diseases; however, the molecular mechanisms involved 
in their beneficial effects are not fully understood. Recent publications point to the fun-
damental role of aldosterone and vascular MR in the regulation of arterial tone, vascular 
contractility, and cell proliferation. However, the intricate transduction machinery acti-
vated by vascular MRs has begun to be revealed with the help of transgenic rodent mod-
els and novel transcriptional analysis approaches. Specifically, in this chapter, we review 
and discuss the most recent contributions about the fine-tuning that the MR exerts on the 
expression and function of ion channels that participate in calcium handling of vascular 
cells and the therapeutic implications for hypertension and cardiovascular diseases.
Keywords: calcium channels, calcium handling, vascular smooth muscle, aldosterone, 
mineralocorticoid receptor
1. Introduction
Recent research efforts on the mineralocorticoid receptor (MR) signaling have revealed a clus-
ter of new pathophysiological mechanism mediated by vascular MR in which aldosterone 
(Aldo) plays a pivotal role; however, the molecular pathways are not completely elucidated. 
In this chapter, we review and discuss novel contributions about the structure, ligand activa-
tion, and additional mechanisms that confer selectivity for Aldo of the MR in vascular tissues. 
In addition, we review the fine-tuning that the MR exerts on the expression and function of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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ion channels that participate in Ca2+ handling of vascular smooth muscle cells and the thera-
peutic implications for hypertension and cardiovascular diseases.
In 1972, Crabbé demonstrated that Aldo was interacting with cytoplasmic receptors and that 
the steroid-protein complex acted as activator triggering the synthesis of mRNA and proteins 
[1]; thus, Aldo was the first identified mammalian steroid hormone that exerted transcrip-
tional actions via some kind of cytoplasmic/nuclear receptors [2]. Several classes of mineralo-
corticoid receptors were identified in both epithelial and surprisingly in non-epithelial tissues 
such as cardiomyocytes, endothelial cells (ECs), and vascular smooth muscle cells (VSMCs) 
[2], auguring the future actions of Aldo in the cardiovascular system.
2. Mineralocorticoid receptor structure and expression in vascular 
tissues
The MR is a ligand-activated transcription factor that belongs to the nuclear receptor super-
family [3]. MR was originated by a process of gene duplication from a common ancestor that 
diverged into the glucocorticoid receptor (GR) and the MR [4]. In 1987 the group of Arriza 
et al. cloned the MR from human placenta [5]. The human MR (hMR) is coded by a unique 
gene (Nr3C2, due to its belonging to the subfamily 3 of nuclear receptors, group C, member 2) 
located in chromosome 4, locus q31.1, and with a length of about 75Kb. The gene encodes a 
polypeptide chain of 984 aa (~107 KDa) [5]. The orthologous gene in rat encodes for a protein 
of 981 aa (Figure 1) and share an identity of 90.1% with the hMR. Nr3C2 contains 10 exons; 
the first 2 of them (1α and 1β) comprise the 5′-noncoding sequences, whereas the following 
exons (2–9) are harboring the functional domains of the protein. It has been reported that at 
Figure 1. Mineralocorticoid receptor structure. Linear representation of rat MR sequence with respective protein 
domains. The MR contains an N-terminal transactivation domain of variable lengths (A/B) and a DNA binding domain 
(DBD) with two zinc fingers involved in the recognition of specific DNA sequences within the promoters of target genes 
and named hormone response elements (HRE); a flexible hinge is connecting the DBD to the ligand-binding domain 
(LBD) in the C-terminal region. The residues N767, Q773, R814, and T942 are part of the ligand-binding pocket. The MR 
also contains three nuclear localization signals (NL0, NL1, and NL2) and multiple phosphorylation sites, and between 
them is Ser843 that is a target of calcium/calmodulin-dependent protein kinase type II (CamKII).
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least three variants of MR mRNA (α, β, and γ) are encoded in a tissue-specific manner under 
the control of different gene promoters [6].
The MR receptor has the same protein structure as other members of the nuclear receptor 
superfamily. The MR is composed of an A/B domain (1–604 aa) with a transactivation func-
tion and several serine and threonine phosphorylation sites [7] and a DNA binding domain 
(DBD, 604–699 aa) with two zinc finger motifs that recognize DNA-specific sequences 
named hormone response elements (HRE), normally found in the promoters of target genes 
[8]. After the DBD, the hinge D region (670–733 aa) is found and, finally, the C-terminal 
region (734–981 aa) that is harboring the ligand-binding domain (LBD) with a pocket (which 
comprises Asp767, Gln773, Arg814, and Thr942) involved in the recognition of agonist and 
antagonist [9] (Figure 1).
2.1. Mineralocorticoid receptor expression in different tissues
The direct and specific actions of Aldo require MR expression in target tissues. For a long 
time, it was thought that MR was expressed exclusively in kidney epithelial cells and that 
Aldo was secreted only by the adrenal gland. However, a cumulative evidence has showed 
the presence of MR in non-epithelial tissues, such as the colon, salivary glands, trachea, heart 
[10], adipocytes [11], brain [5], skeletal muscle [12], leucocytes, macrophages [13], and vessels 
[14–19] (Table 1).
Tissue or cell type Detection method Reference
Kidney NB [5]




Skeletal muscle WB [12]
Endothelial cells RT-PCR [17]
Vascular tissues
Aorta Im, WB, [3H]Aldo bindings [10, 16, 19, 21, 22]
Carotid artery Im [10]
Cerebral artery WB [18]
Coronary artery RT-PCR, Im, WB [10, 16, 19]
Humeral artery Im [10]
Mesenteric artery Im, RT-PCR, WB [10, 15, 19]
Pulmonary artery Im, NB [10, 14]
Renal artery Im [10]
Saphenous vein RT-PCR, WB, WB [23]
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Specifically in blood vessels, the group of Marc Lombѐs showed for the first time the expres-
sion of MR in ECs and SMCs of the aorta and pulmonary artery by immunostainings and 
[3H]Aldo binding [10]. Although with a low level of immunostaining signal, the MR was 
found in small arteries such as the carotid, humeral, mesenteric, coronary, and renal arteries. 
Interestingly, neither immunostaining nor [3H]Aldo binding allowed the detection of MR in 
the vena cava and portal vein [10]. Hatakeyama et al. detected MR mRNA in primary cultures 
of ECs and SMCs from human pulmonary arteries [14]. Later, Takeda et al. demonstrated the 
presence of MR mRNA in mesenteric arteries of stroke-prone spontaneously hypertensive 
rats (SHRSP) [15]. Using RT-PCR the MR mRNA was detected in a human aorta [21]. Jaffe 
and Mendelsohn also demonstrated that MR was expressed in VSMCs from aorta and heart 
vasculature, specifically in coronary arteries [16]. In the case of cerebral arteries (CA), MR 
expression has been showed by Western blots, where MR levels were higher in CA from 
females than males [18]. All of these data established the foundation for understanding MR 
action in vascular tissues. Nowadays we know that MR is indeed expressed in the cardiovas-
cular system supporting its direct role in vascular pathophysiology.
3. Mineralocorticoid receptor: mechanism of activation and 
regulation in vascular tissues
In basal conditions, the MR is located at the cytoplasm forming a complex with heat-shock 
proteins, Hsp90 and Hsp70, that stabilize its structure in a conformation where the ligand-
binding site is ready to interact with the hormone [24, 25]. Once the ligand is bound, the 
MR is subjected to a series of conformational changes (Figure 2). The interaction between 
N-terminal and C-terminal domains of MR induces the dissociation of heat-shock proteins 
and corepressors, allowing MR translocation to the nucleus. However, it has been reported 
also that Hsp90 follows MR into the nucleus [26]. Inside the nucleus the MR dimerizes, binds 
to HRE, and recruits a co-regulator complex to induce the transcription of target genes [27, 28]. 
Interestingly, in some animal models of kidney and cardiac injury that showed normal plasma 
Aldo concentrations, the MR is activated through a ligand-independent pathway, involving a 
direct interaction between a small GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1) 
and the MR [29], though evidence of this pathway is still lacking in vessels.
Tissue or cell type Detection method Reference
Umbilical vein [23]
Adipocytes Im [11]
Macrophages PCR, Im [13]
Lymphocytes PCR [13]
Im, immunohistochemistry; NB, Northern blot; PCR, polymerase chain reaction; RT-PCR, reverse transcription 
polymerase chain reaction; WB, Western blot technique.
Table 1. Cell types and tissues expressing MR.
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The high homology between the LBD structure of MR and GR receptors helps to explain why 
the MR binds cortisol and corticosterone and glucocorticoids with similar affinity with Aldo 
[33]. Cortisol and Aldo bind to hMR with similar affinity [5, 9]. Because the serum levels of 
cortisol are higher (from 100 to 1000 times more) than Aldo, then it is expected that the occu-
pancy of MR by cortisol predominates. However, a mechanism that confers MR selectivity for 
Aldo depends on the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2), which 
converts cortisol to cortisone, the latter has a low affinity for MR [34]. Several papers have 
demonstrated the co-expression of MR with a functional 11βHSD2 in different vascular beds 
including mesenteric [15] and coronary arteries [16, 35], though with an indirect determina-
tion in CA [36]. These studies support that vascular tissues are Aldo-specific targets and that 
the action of 11βHSD2 is the physiological mechanism that excludes the activation of MR by 
cortisol. Furthermore, these data support that the MR-Ado complex has greater stability and 
higher transcriptional efficiency than the MR-cortisol complex [9].
3.1. Importation of MR into the nucleus
Immunostainings of MR in SMC from coronary arteries have showed the presence of MR 
in both cytoplasm and nucleus, even in the absence of a ligand. After exposure to Aldo, MR 
Figure 2. Schematic representation of the MR activation mechanism by Aldo in vascular smooth muscle cells. Once MR 
binds Aldo in the cytoplasm, it is subjected to conformational changes that allow the dissociation of heat-shock proteins 
(Hsp70/90), the unmasking of nuclear localization signal, and finally the MR translocation to the nucleus where the MR 
dimerizes (homodimer complex) and binds to hormone response elements (HRE). The MR dimer recruits a co-regulator 
complex for regulating the transcription of target genes. Both Aldo and cortisol bind to MR with similar affinity. The 
mechanism that confers MR selectivity for Aldo depends on the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11 
βHSD2), which converts cortisol to cortisone, the latter has a low affinity for MR. Some of the MR target genes in SMC 
from different vascular beds are listed [19, 30–32]. Abbreviations: Cacna1a, VDCC subunit alpha1 A; Kcnma1, BK
Ca
 channel 
(alpha subunit); Kcnmb1, BK
Ca
 channel (beta subunit 1); Trpc1, transient receptor potential cation channel subfamily c 
member 1; Trpc6, transient receptor potential cation channel subfamily c member 6; Stim1, stromal interaction molecule 
1; Orai1, ORAI calcium release-activated calcium modulator 1.
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is located mainly in the nucleus [16]. Like other nuclear receptors, the MR is a protein of a 
considerable molecular mass (~107 KDa) that exceeds the calculated size for its passive diffu-
sion through the nucleus; thus, it requires specific signals for its nuclear transport. Specifically 
the importation of MR into the nucleus is controlled through three nuclear localization sig-
nals (NLS): the first NLS (NL0) is a serine-/threonine-rich sequence located at the N-terminal 
region, the second is a NLS (NL1) located at the DBD, and the third is a NLS (NL2) within 
the LBD. The presence of several NLS in different regions of the MR structure suggests a 
redundant mechanism to assure its mobilization toward the nucleus as part of the essential 
mechanism of its transcriptional activity [37].
3.2. MR posttranslational modifications
The MR is subjected to several posttranslational modifications (PTM) such as phosphoryla-
tion, ubiquitination, sumoylation, and acetylation that regulate its localization, activity, and 
stability. Phosphorylation is the most common PTM since the MR contains more than 30 
(putative and experimentally assessed) phosphorylation sites that allow to consider it as a 
phosphoprotein (Figure 2). The multiple phosphorylation sites of the MR generate a double 
band in SDS-PAGE due to a shift of approximately 30 kDa in its apparent molecular mass. 
The physiological function of all these phosphorylation sites is still under study or completely 
unknown as in the case of vascular MR. A report has shown that the phosphorylation of 
Ser843 (in the LBD) prevents MR ligand binding and activation [38]. In contrast, Amazit et al. 
reported an increase in the MR phosphorylation after Aldo binding, suggesting a ligand-
dependent process [39]. Walther et al. reported that phosphorylation of residues inside the 
NL0 might modulate the MR transport into the nucleus [37]. Finally, Faresse et al. found that 
the MR is monoubiquitinylated at its basal state and that the Aldo-stimulated MR phosphory-
lation induces its polyubiquitinylation, destabilization, and degradation [40]. The physiologi-
cal role of MR-PTM has not been determined in VSMCs.
3.3. Genomic effects of aldosterone in vessels
Aldo exerts its effects in vascular tissues via non-genomic (which are not subjects of this chap-
ter) and genomic MR-dependent pathways. In the case of MR-dependent genomic actions in 
VSMCs, Jaffe and Mendelsohn investigated the MR-mediated gene transcription activity in 
SMC of human coronary arteries (HCSMCs) by microarray and quantitative RT-PCR assays. 
These researchers showed that Aldo modulated the expression of VSMC genes that contribute 
to vascular inflammation and fibrosis. Additionally, by using a MR response element (MRE) 
reporter driving the expression of the luciferase gene, they demonstrated that Aldo activated 
MR in HCSMCs. The Aldo transcriptional effects were regulated in a dose-dependent man-
ner, starting at 1 nM, which is consistent with the Kd for Aldo-MR interaction of ~1–2 nM [16]. 
Similarly, Newfell et al. evaluated the gene expression profile in Aldo-treated aorta ex vivo, 
identifying 72 genes that were regulated by Aldo, some of them in a concentration-dependent 
fashion (1, 10, 30, and 100 nM). Between the Aldo-regulated genes, several of them are involved 
in oxidative stress, nitric oxide (NO) signaling, vascular proliferation, and fibrosis. Moreover, 
it has been showed that the MR transcriptional activity is blunted by MR antagonists, and 
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actinomycin D (a transcriptional inhibitor) supporting an MR-dependent effect of Aldo in 
vessels [16, 19, 30, 41]. Furthermore, an increasing body of evidence has underlined the ability 
of MR to modulate the expression of ion channels in several vascular beds, unveiling the role 
of MR in vascular physiology and pathology [19, 30, 42, 43].
4. Pathological role of vascular mineralocorticoid receptor in blood 
vessels
It has been confirmed that MR presents extrarenal actions [42, 44, 45] as Na+ handling alone 
cannot fully explain the development of hypertension and associated cardiovascular mortal-
ity; but these actions are still poorly understood. In fact, there are multiple clinical studies in 
which mineralocorticoid receptor antagonists (MRA) reduce the incidence of heart attacks 
and cardiovascular mortality [46, 47].
4.1. Role of vascular MR in oxidative stress
In vitro and in vivo data suggest a vascular MR activation in stimulating oxidative stress, 
inhibiting vascular relaxation, and contributing to vessel inflammation, fibrosis, and remod-
eling. MR activation may promote vascular aging and atherosclerosis contributing to the 
pathophysiology of heart attack, stroke, and possibly hypertension [42]. The balance between 
damaging reactive oxygen species (ROS) and protective NO determinates the vascular oxida-
tive stress. ROS interact with NO decreasing the NO bioavailability. In vivo experiments in 
rats support that activation of MR signaling contributes to the vascular dysfunction induced 
by βAR overstimulation associated with endothelial NO synthase uncoupling reducing NO 
production and bioavailability [48]. Meanwhile, in the presence of endothelial dysfunction, 
vascular injury, or high vascular oxidative stress (for instance, in patients with cardiovascu-
lar risk factors), ROS production increases via VSMC-MR-mediated activation of NADPH 
oxidase (a ROS generator) [23, 49, 50] promoting impaired EC-dependent vasorelaxation and 
consequently increasing vasoconstriction and blood pressure (BP) [51].
4.2. Role of MR in vascular remodeling
Vessel injury induces a pathological response termed vascular remodeling which contrib-
utes to human ischemic vascular disease. Adverse vascular remodeling limits vessel lumen 
diameter and increases vascular stiffness associated with fibrosis, thereby contributing to 
organ ischemia and hypertension. MR activation contributes to vascular remodeling by act-
ing synergistically with endothelial damage, angiotensin II (Ang II), platelet-derived growth 
factor (PDGF), and epidermal growth factor (EGF) [52–55]. These processes involve both 
genomic (upregulation of genes involved in cell migration, proliferation, and matrix modula-
tion) and non-genomic mechanisms (via MAPK and the c-Src/Rho) [56]. In the pulmonary 
artery, MR activation induced the proliferation of VSMC, an effect prevented by spirono-
lactone [57]. Moreover, in a VSMC-MR knockout mouse model, carotid injury-induced and 
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aldosterone-enhanced vascular fibroses were attenuated; thus, VSMC-MR is necessary for 
aldosterone-induced vascular remodeling [58]. In aged VSMC-MR-deficient mice (18-month-
old), a decrease in aortic collagen content was found [42], suggesting that VSMC-MR play 
a role in vascular fibrosis. Unlike in an aldosterone/salt hypertension model, the specific 
VSMC-MR inactivation also leads to the attenuation of arterial stiffening preventing the cell-
matrix attachment proteins but without significant modification in vascular collagen/elastin 
ratio [22]. Other studies support that, after injury, aldosterone-infused animal developed 
vascular remodeling and MR antagonist reversed those effects [59–61]. Pharmacological 
inhibition of MR has also demonstrated beneficial effects such as increased lumen and outer 
diameters of the middle cerebral artery of spontaneously hypertensive stroke-prone rats [62]. 
Moreover, in a clinical study, treatment with the MR antagonist eplerenone improves the 
degree of arterial stiffness in hypertensive patients [63]. In conclusion, these studies support 
that VSMC-MR plays a direct role in vascular remodeling.
4.3. Participation of MR in vascular inflammation
MR plays a key role in the pathogenesis of vascular disease including atherosclerosis and 
hypertensive vasculopathy, where the role of inflammation has been studied in the last years. 
In patients with atherosclerosis, high levels of aldosterone in serum predict a substantial 
increase in subsequent myocardial infarction or death. In vitro studies with human VSMC and 
ECs have shown that MR activation directly promotes the expression of inflammatory genes 
[64]. Interestingly, in an in vivo model, spironolactone reduced the number of inflammatory 
cells in the grafted vein without changing total SMC content, suggesting that MR signaling 
may contribute to graft remodeling through inflammatory processes rather than SMC hyper-
trophy [65]. Moreover, in experimental models of atherosclerosis, it was confirmed that the 
plaque progression was enhanced by Aldo and prevented by MR antagonists [66–68]. The 
pro-atherogenic genes (CTGF, MT1, and PGF) are also vascular MR-regulated genes [41]. 
MR signaling also contributes to vascular inflammation in animal models of hypertension. 
In experimental models of hypertension, MR inhibition reduced the vascular inflammation 
even without changes in BP, supporting that MR activation participates in vascular inflamma-
tion and damage through a BP-independent process [69]. Vascular calcification is a late stage 
found in atherosclerosis, particularly in the elderly and in patients with renal failure [70]. In 
VSMCs from human coronary artery, MR activation by Aldo upregulated the expression of 
genes implicated in vascular calcification, including bone morphogenetic protein 2 (BMP-2), 
alkaline phosphatase (ALP), and osteoprotegerin [16]. Also, in an in vitro model, MR activation 
by Aldo or cortisol stimulated vascular ALP [71]. MR is also involved in vascular calcifica-
tion by regulating the expression of the phosphate transporter Pit1, which has an osteogenic 
function in the smooth muscle ameliorated by spironolactone [72]. However, in a different 
in vitro study using VSMC isolated from the aorta, it was showed that pro-calcification effects 
of corticosterone and 11-DHC are mediated directly by MR, but the expression of Osterix, 
BMP-2, and Pit-1 was unaltered [73]. These in vitro studies support that MR is involved in 
the late stage of atherosclerosis: vascular calcification. All these studies support that vascular 
MR activation participates in the inflammatory response and contributes to the complications 
associated with atherosclerotic vascular disease.
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4.4. Vascular MR and hypertension
Hypertension represents an aging-associated cardiovascular risk factor. It is known that renal 
MR regulates the BP and the MR has been considered an antihypertensive target for decades. 
The association between high levels of Aldo and hypertension was proposed when some 
forms of hypertension were found associated to primary hyperaldosteronism; also, the posi-
tive correlation of high levels of Aldo with high MR expression and hypertension has pointed 
out to a key role of MR in the establishment of the hypertensive phenotype. Moreover, about 
50 years ago, the MR antagonist spironolactone decreased BP in hypertensive patients [74] 
and in patients with other types of hypertension [75]. The antihypertensive effects of MRA 
have been analyzed in clinical trials demonstrating a BP reduction in hypertensive patients 
with primary aldosteronism [76–78] with no changes in plasma K+ concentration, a marker 
of renal MR activation [44, 79]. The meta-analysis by Dahal et al. showed that spironolactone 
reduced systolic BP and this effect was not associated with an increased risk of hyperkalemia 
compared to placebo [80]. Antihypertensive effects of MRA were analyzed also in resistant 
hypertension that affects at least 10–15% of all patients. Several studies support that low-dose 
spironolactone provides significant additive BP reduction in subjects with resistant hyper-
tension [75, 81–85]. PATHWAY-2 was the first randomized and controlled trial to compare 
spironolactone with other BP-lowering drugs in a well-characterized population of patients 
with resistant hypertension. In this study it was demonstrated that MRA reduced systolic BP 
with no hyperkalemia risk [86]. In addition, a role of MR in pulmonary hypertension has been 
recently identified. MRA treatment initiated at the time of the pulmonary arterial hypertension 
stimulus prevents the pulmonary vascular hyperplasia and reduces systemic BP [57, 87]. Thus, 
MR activation may be equally important in patients with and without an established diagnosis 
of primary aldosteronism. The pathogenesis of MR-associated hypertension in the presence of 
physiological levels of Aldo in plasma might be mediated by MR activation by other pathways, 
for instance, MR overexpression, sensitivity, and/or overstimulation by other factors.
The effect of MR blockade in the development of hypertension has been also assessed in 
experimental models. In the Dahl salt-sensitive model, MRA attenuated the progressive rise 
in systolic BP in rats fed with a high-salt diet [88, 89]. Whole body disruption of MR in mice 
results in neonatal lethality from dehydration by renal Na+ and water loss; thus, transgenic 
mouse models allowing cell-specific targeting of MR expression have been used to under-
stand the role of MR in vascular tissues and its potential implication in BP regulation. The par-
ticipation of vascular MR in BP regulation has been analyzed by using two different mouse 
models: a tamoxifen-inducible VSMC-specific MR inactivation model (via the smooth muscle 
actin promoter [42]) and a constitutive model of VSMC-specific MR inactivation (via the SM22 
promoter; [22]). No transgenic models with targeted MR overexpression in the VSMCs have 
been reported yet.
The genetic inactivation of MR in adult (2 months of age) mice prevented the increase in 
BP induced by aging. SMC-MR-deficient mice developed reduced spontaneous myogenic 
tone. However, the vascular structure and stiffness of resistance arteries from aged SMC-
MR-deficient were similar to those from control mice, supporting the notion that SMC-MR 
contributes to vascular tone and BP regulation independently of structural changes in the 
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vasculature [42]. The constitutive model of VSMC-specific MR inactivation reported a similar 
basal BP decrease in 5-month-old MR-KO mice [22]. The BP phenotype in both inactivated 
VSMC-MR model mice is independent of Na+ intake and renal MR function supporting a 
role for VSMC-MR in BP regulation. Interestingly, tamoxifen-inducible VSMC-MR inactiva-
tion prevented the in vivo increase in BP induced by Ang II infusion but not by aldosterone-
salt challenge [22, 42]. Inactivation of VSMC-MR was also shown to decrease the contractile 
response to KCl and extracellular Ca2+ [62]. The role of the vascular MR could also depend on 
the vascular bed that is considered. In the future, the use of transgenic models will allow us 
to decipher the contribution of endothelial MR and VSMC-MR in the different vascular beds 
and the possible implication in BP regulation [90].
5. Calcium handling proteins are targets of vascular MR receptors
5.1. L-Type Ca2+ channel
Recognized as a universal second messenger in various cellular processes and cell types, 
Ca2+ signal plays a critical role in many cellular processes, including, but not limited to, gene 
transcription and excitation-contraction (EC) coupling [91, 92]. Although almost all biological 
responses are mediated by Ca2+-dependent and Ca2+-controlled processes, Ca2+ signals need 
to be finely coordinated and precisely regulated. Ubiquitously expressed in the whole body, 
Ca
v
1.2 is the main route of Ca2+ entry in VSMCs, essential for vascular EC coupling and control 
of myogenic tone [93]. As a heteromultimeric channel, L-type Ca2+ channel (LTTC) is formed 








1.2γ. Undebatable the 
main subunit, the pore-forming Ca
v
1.2α1C region, has also been the target of drugs with anti-
hypertensive properties [94–96], although its effectiveness has been achieved only in a subset 
of hypertensive patients [97]. Importantly Ca
v
1.2α1C channels are expressed as two distinct 
tissue-specific transcripts of Cacna1c driven by two alternative promoters P1 and P2, encoding, 
respectively, for a long “cardiac” (Ca
v
1.2-LNT) and for a short “vascular/brain” (Ca
v
1.2-SNT) 
N-terminal region [98]. In VSMCs, LTTC is activated in response to the membrane depolariza-
tion, allowing a small fraction of Ca2+ influx, which is sufficient to trigger VSMC contraction. 
Thus, sustained voltage-dependent Ca2+ influx through the LTCCs maintains a tonic level 
of vasoconstriction and provides an excitatory template upon which endogenous vasoactive 
substances may act to modulate arterial diameter and BP.
Although previous studies have demonstrated that aldosterone modulates VSMC Ca2+ cur-
rents [99–101], the mechanisms remain to be determined. A landmark study showed that 
VSMC-specific MR knockout mice (VSMC-MR-KO) are protected against the age-associated 
rise of BP [42]. Importantly, aged VSMC-MR-KO mice showed decreased myogenic tone 
and attenuated vascular contraction in mesenteric arteries in response to a LTCC opener. 
Moreover, mRNA level of Ca
v
1.2α1C subunit was dramatically downregulated in aortas 
from aged VSMC-MR-KO mice, suggesting that MR may regulate VSMC Ca
v
1.2 expres-
sion. However, this phenomenon seems indeed to be an age-dependent effect, since a latter 
study did not validate, at protein level, the downregulation of Ca
v
1.2 in aortas from young 
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VSMC-MR-KO mice [102]. Furthermore, during the aging process, MR expression increases 
in resistance vessels along with a decline in the microRNA (miR)-155 abundance, suggesting 
that Ca
v
1.2 is a downstream target of miR-155 regulation [103].
Adding more pieces to the puzzle, we recently showed in cardiomyocytes that aldosterone 
regulates Ca
v
1.2-LNT by recruiting MR onto targeted genomic regions in “cardiac” Cacna1c 
P1-promoter [19]. Importantly, we deciphered that aldosterone, through MR-dependent 
mechanism, dramatically activates the “cardiac”-specific Cacna1c P1-promoter, even in blood 
vessels, conferring a new molecular signature to Ca
v
1.2α1C in this tissue that minimizes Ca2+ 
channel blocker actions, a mechanism that might participate to treatment-resistant hyperten-
sion, as recently proposed [86]. These findings were further validated using a hypertensive 
rat aldosterone-salt model, as previously described [104]. Although our data showed that 
aldosterone/MR impairs 1,4-dihydropyridine sensitivity in VSMC through alternative splic-
ing of Ca
v
1.2α1C, further studies are needed to validate whether this mechanism participates 
in the resistant hypertension.
5.2. Ca2+-activated potassium channels
Ca2+-activated potassium channels (KCa), mainly the large conductance KCa channels 
(BKCa), have been recognized as another important target of MR in blood vessels [105]. BKCa 
plays a critical role in limiting arterial contraction by producing VSMC hyperpolarization 
through transient outward K+ current in response to increased intracellular Ca2+ concentra-
tion [106]. However, three subtypes of KCa have been identified in blood vessels and cat-
egorized according to their conductance: small (SKCa), intermediate, and BKCa. Small- and 
intermediate-conductance channels are mainly expressed in the ECs, while BKCa channels 
are predominately expressed in VSMCs.
Previous studies have shown that increased plasma aldosterone concentration enhances 
vascular KCa function [105]. Oppositely, it was demonstrated that mice lacking the pore-
forming BKCaα subunit led to an elevation of BP resulting from hyperaldosteronism, which 
was accompanied by decreased serum K+ levels, as well as increased vascular tone in small 
arteries [107]. Accordingly, impaired acetylcholine-mediated relaxation in isolated coronary 
arteries has been shown in mice model with cardiac-specific overexpression of aldosterone 
synthase (MAS mice) [30]. These findings correlate with decreased mRNA and protein expres-
sion of BKCa α and β1 subunits in the heart and coronary artery of MAS mice. Moreover, 
in vitro treatment of rat aortic VSMCs with increasing concentrations of aldosterone led to 
a reduced BKCa subunit expression in a concentration-dependent manner. Thus, these find-
ings suggest that augmented local aldosterone production likely acts in a paracrine fashion 
way suppressing BKCa expression in the surrounding coronary VSMC, thereby contribut-
ing to the impaired endothelium-dependent VSMC relaxation. Intriguingly, despite aged 
VSMC-MR-KO mice displaying lower BP than age-matched WT mice, no significant changes 
were observed in aortic mRNA expression and function of BKCa in mesenteric VSMC [42]. 
Furthermore, aldosterone-treated aorta for 24 h with 10−8 M of aldosterone did not modify 
mRNA expression of BKCa α and β1 subunits [19]; thus, further studies are needed to clarify 
the effect of MR activation in the expression and activity of BKCa channels.
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As mentioned above, SKCa is predominantly expressed in ECs, where it contributes to endo-
thelium-derived hyperpolarization (EDH) of VSMC resulting in vasorelaxation of resistance 
arteries [108]. In a previous study, circulating aldosterone level was significantly higher in 
mice fed with high-fat diet (HFD) compared to lean mice; however, despite the restoration of 
endothelium-dependent vasodilation, eplerenone treatment further increased plasma aldo-
sterone levels of HFD-fed obese mice [109]. Recently, using similar obese model, plasmatic 
aldosterone concentration was also augmented in male and female mice, whereas no change 
was found in endothelial cell-specific MR knockout mice (EC-MR-KO) subjected to HFD 
[110]. In males, obesity impaired NO-dependent vasodilation of resistance arteries, which 
was compensated by enhancement of EDH of VSMC along with an increase in mesenteric 
protein expression of SKCa3, while any change was observed in EC-MR-KO. On the other 
hand, in females, EDH component of VSMC relaxation was impaired, whereas the expres-
sion of SKCa3 remained unchanged in control and EC-MR-KO underwent to HFD [110]. 
Altogether, these results uncover distinct sex-specific mechanisms driving vascular dysfunc-
tion, suggesting personalized therapies to prevent vascular disorders.
5.3. Transient receptor potential channels
In VSMC, Ca2+ entry from the extracellular space involves a variety of plasmalemmal Ca2+ 
channels, which also involve the superfamily of transient receptor potential (TRP) channels, 
such as TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), and TRPP (polycystin) [111]. 
Widely expressed in visceral and vascular SMC, changes in the expression and activity of 
these channels are implicated in a variety of physiological and pathophysiological conse-
quences [112]. Although TRPM subfamily contains eight isoforms (TRPM1–8), which exhibit 
a variety of cation permeability, only TRPM6 and M7 seems to be Ca2+ and Mg2+ permeable. 
Interesting, aldosterone (100 nM) transiently upregulates mRNA TRPM7 expression in rat 
VSMC from 2 to 6 h after the onset of treatment, restoring to control level after 24 h of treat-
ment [113]. However, up to date, no studies have been done to evaluate whether aldosterone 
modulates the expression of TRPV and TRPP channels.
Originally thought to contribute solely to restoring Ca2+ concentration under store depletion, 
creating a capacitative Ca2+ entry, commonly termed as store-operated Ca2+ entry (SOCE), the 
role of SOCE is much more diverse than just refilling Ca2+ stores [114] but also contributing 
to vascular contractility, VSMC proliferation, and differentiation [112]. In addition, Ca2+ entry 
from the extracellular space may also occur through Ca2+-permeable store-independent chan-
nels, named as receptor-operated channels (ROC), which their activity depends on second 
messengers produced by downstream effectors from a vast array of G protein-coupled recep-
tors [114]. TRPC subfamily comprises seven members (TRPC1–TRPC7), with the TRPC2 gene 
being a pseudogene in humans [114].
Although TRPC1 seems to be the most abundant isoform expressed in rat mesenteric arter-
ies, only the expression of TRPC6 was increased in deoxycorticosterone acetate (DOCA)-salt 
hypertensive rats [31]. Moreover, A7r5 cells treated with aldosterone (1 μM for 24 h) also 
displayed increased mRNA and protein levels of TRPC6 [31]. Accordingly, it was shown 
that coronary rings cultured for 7 days with aldosterone (100 nM), without fetal bovine 
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serum to preserve the contractile phenotype, displayed higher coronary contractility in 
both endothelium-denuded and endothelium-intact rings, while co-treatment with spirono-
lactone prevented this effect [115]. Recently, we demonstrated that rat aorta treated with 
aldosterone (10 nM for 24 h) did not reveal changes in the expression of TRPC1, C3, C4, C5, 
and C6 [19]. Altogether, these studies suggest a concentration-dependent increase of TRPC 
channels, since we have previously demonstrated an upregulation of TRPC1, C4, and C5 in 
cardiomyocytes upon aldosterone concentrations higher than 100 nM [43]. Moreover, one of 
the features of metabolic syndrome is the elevated plasma aldosterone level [116], which has 
been associated with increased TRPC1 and TRPC6 expression in coronary arteries compared 
to lean pigs [32].
Another critical component of SOCE is the protein Orai (comprising Orai1, Orai2, and Orai3), 
which forms a family of highly Ca2+-selective channels that are regulated by stromal-interacting 
molecules (STIM1 and STIM2) [111, 112]. In neonatal cardiomyocytes, Orai1 was significantly 
increased by 100 nM and 1 μM aldosterone treatment, whereas lower concentrations (1 and 
10 nM) had no effect [43]. However, Stim1 expression remained unchanged even at the high-
est concentration tested (1 μM) [43]. Similarly, we recently observed, in blood vessels, that 
treatment with 10 nM of aldosterone for 24 h does not affect the expression of either Orai1 or 
Stim1 [19].
6. Perspectives
Hypertension is a substantial public health problem, affecting 25% of the adult population 
in industrialized societies. This disorder is a major risk factor for many common causes of 
morbidity and mortality including stroke, myocardial infarction, congestive heart failure, and 
end-stage renal disease. Thus, substantial effort has been devoted to defining the pathogen-
esis of BP variation. Aldo, through the activation of MR in tubular epithelial cells, has a well-
known function on water balance and BP homeostasis. The renal hemodynamic consequences 
of excess mineralocorticoids—Na+ and water retention and K+ secretion—ultimately lead to 
hypertension. However, the kidney is no longer regarded as the primary site for mineralo-
corticoid modulation of BP. MR is consistently expressed in both ECs and VSMCs of blood 
vessels, and its activation by Aldo at pathological concentrations (10 nM) is associated with 
several types of vascular dysfunction, including atherosclerosis and hypertension. However, 
despite the recent understanding about the mechanisms involved in the activation of MR 
mainly in pathological conditions, further research is still required to determine the physi-
ological role of MR-VSMCs in blood vessels.
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